Hi,
I remember seeing a 20-40M for the market size of the Remodulin...and they projected a 75-100M revenues for 02 in the last filing.
Actelion was also approved and could be a serious competitor if the side effects do not present too many problems..
Also, the short position (20%)could create a spike if some interesting news come up....
Now, of course, we need some interesting news....:)
September looks like it will be the last terrible leg before a rally. But how sustainable will it be? I expect the housing sector to crash down very shortly.What do you think?